Skip to main content

Table 4 Results of a 6-arm factorials study of the acute treatment of migraine and TTHa [33]

From: Caffeine in the management of patients with headache

Measure AAC-100 APAP + ASA APAP ASA Caffeine Placebo
PID @ 2 h (mm) 44.7 40.2 39.5 40.7 31.4 24.6
 Active vs placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.02
 Active vs AAC-100 0.002 0.02 0.003 <0.0001 <0.0001
Weighted SPID (%) 66.6 62.0 57.5 62.2 46.7 40.2
 P vs placebo <0.0001 <0.0001 <0.0001 <0.0001 0.0993
 P vs AAC-100 0.02 0.07 0.0002 <0.0001 <0.0001
Functional disability @ 2 h (%) 53.9 49.4 48.6 48.4 39.4 30.5
 P vs placebo <0.0001 <0.0001 <0.0001 <0.0001 0.1491
 P vs AAC-100 0.08 0.08 0.04 <0.0001 <0.0001
Global assessment of efficacy (%) 25.2 21.4 15.4 18.7 20.8 10.9
 P vs placebo <0.0001 <0.0001 <0.0001 <0.0001 0.0132
 P vs AAC-100 0.01 <0.0001 0.009 <0.0001 <0.0001
  1. AAC-100, acetaminophen 400 mg, aspirin 500 mg, caffeine 100 mg per 2-tablet dose; APAP + ASA, acetaminophen 400+ aspirin 500 mg per 2-tablet dose; APAP, acetaminophen 400 mg per 2-tablet dose; ASA, aspirin 500 mg per 2-tablet dose; caffeine, caffeine 100 mg per 2-tablet dose; PID, pain intensity difference from baseline; SPID, sum of pain intensity differences
  2. aThe study population included patients with migraine (84%) and TTH (13%) who typically treated attacks with non-prescription analgesics